K10, hFF-iPSCs
MILi001-A
General
Cell Line |
|
| hPSCreg name | MILi001-A |
| Cite as: | MILi001-A (RRID:CVCL_A8MM) |
| Alternative name(s) |
K10, hFF-iPSCs
|
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Similar lines | |
| Last update | 17th January 2022 |
| User feedback | |
Provider |
|
| Generator |
Miltenyi Biotec B.V. & Co. KG (MIL)
Contact:
Miltenyi Biotec B.V. & Co. KG (MIL) |
| Owner | Miltenyi Biotec B.V. & Co. KG (MIL) |
| Distributors | |
| Derivation country | Germany |
External Databases |
|
| BioSamples | SAMEA9086589 |
| Cellosaurus | CVCL_A8MM |
| Wikidata | Q108820931 |
General Information |
|
| Publications |
|
| Projects | |
| * Is the cell line readily obtainable for third parties? |
No |
Donor Information
General Donor Information |
|
| Sex | male |
Phenotype and Disease related information (Donor) |
|
| Diseases | No disease was diagnosed.
|
| Family history | n.a. |
| Is the medical history available upon request? | no |
| Is clinical information available? | no |
Karyotyping (Donor) |
|
| Has the donor karyotype been analysed? |
Unknown
|
Other Genotyping (Donor) |
|
| Is there genome-wide genotyping or functional data available? |
Yes
SNP typing array
Amelogenin: X,Y CSF1PO: 10,12 D13S317: 8,9 D16S539: 9,13 D5S818: 12 D7S820: 11,12 TH01: 7,8 TPOX: 10,11 vWA: 16,18 |
Donor Relations |
|
| Other cell lines of this donor | |
External Databases (Donor) |
|
| BioSamples | SAMEA5176968 |
Ethics
| Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | No |
| Was the consent voluntarily given? | No |
| Has the donor been informed that participation will not directly influence their personal treatment? | No |
| Can you provide us with a copy of the Donor Information Sheet provided to the donor? | No |
| Do you (Depositor/Provider) hold the original Donor Consent Form? | No |
| If you do not hold the Donor Consent Form, do you know who does? | No |
| Alternatives to consent are available? | Yes |
| Alternatives to consent | MTA, Ethical vote |
| Alternative consent approval number | |
| Has the donor agreed to be re-contacted? | Unknown |
| Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | anonymised |
| Does consent explicitly allow the derivation of pluripotent stem cells? | Yes |
| * Does consent expressly prevent the derivation of pluripotent stem cells? | No |
| * Does consent pertain to a specific research project? | No |
| Does the consent permit uses of donated embryo/tissue or derived cell line intended for clinical treatment or human applications? | No |
| Does consent expressly prevent development of commercial products? | Yes |
| Does consent prevent the DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
| Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
Does consent permit research by | |
| an academic institution? | Yes |
| a public organisation? | Yes |
| a non-profit company? | Yes |
| a for-profit corporation? | Yes |
| How may genetic information associated with the cell line be accessed? | No information |
| Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
| Name of accrediting authority involved? | Ethik-Kommission der Ärztekammer Nordrhein |
| Approval number | 2021472 |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? | Yes |
| Name of accrediting authority involved? | Ethik-Kommission der Ärztekammer Nordrhein |
| Approval number | 2021472 |
| Do you have obligations to third parties in regard to the use of the cell line? | Yes |
| Please describe: | as outlined in MTA |
| Is there an MTA available for the cell line? | Yes |
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? | Miltenyi Biotec B.V. & Co. KG |
| Are you aware of any constraints on the use or distribution of the cell line from the owner or any parties identified in the query above? | Yes |
| Constraints for use or distribution | only to be distributed upon approval of ATCC according to MTA |
hIPSC Derivation
General |
|
| Source cell line name |
BJ Other names
Derived from same source line (potentially other lot and donor, see below):
|
| Source cell type |
Synonyms
|
| Source cell origin | |
| Source cell type (free text) | ATCC® CRL-2522 |
| Source cell line vendor | ATCC |
| Passage number reprogrammed | n.a |
Reprogramming method |
|
| Vector type | None |
Vector free reprogramming |
|
| Type of used vector free reprogramming factor(s) |
mRNA
|
| mRNA | |
Other |
|
| Selection criteria for clones | Expression of TRA-1-60, immunomagnetic selection MACS, subcultivation, morphology |
| Derived under xeno-free conditions |
Yes |
| Derived under GMP? |
No |
| Available as clinical grade? |
No |
Culture Conditions
| Surface coating | Laminin |
| Feeder cells |
No |
| Passage method |
Enzymatically
TrypLE
|
| O2 Concentration | 20 % |
| CO2 Concentration | 5 % |
| Medium |
Other medium:
Base medium: StemMACS iPS-Brew XF
Main protein source: Serum concentration: % |
| Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | Yes |
| Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | No |
| Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | Yes |
Characterisation
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
| POU5F1 (OCT-4) |
Yes |
|
||||
| TRA 1-60 |
Yes |
|
||||
| SOX2 |
Yes |
|
||||
| NANOG |
Yes |
|
|
|||
| SSEA-1 |
No |
|
Score:
| Marker | Present | Absent |
| mCpG | ||
| OCT4 |
Morphology pictures
day 5 of cultivation / TrypLE single cell splitting
day 5 cultivation / StemMACS Passaging solution (cluster passaging)
StemMACS™ Trilineage Differentiation Kit, human
Method documentation
StemMACS™ Trilineage.pdf
User Manual StemMACS Trilineage Differentiation Kit, human
Flow cytometric analysis_Trilineage Kit.pdf
Application Note Tri Lineage Assay
Differentiation Potency
In vivo teratoma
In vitro spontaneous differentiation
In vitro directed differentiation
Other
| Marker | Expressed |
| Sox17 - SRY-box transcription factor 17 |
Yes |
| CXCR4 |
Yes |
Morphology
Teratoma Endoderm
K10 Endoderm ICC_CXCR4 rot_Sox17 grün_Draq5.tif
red: CXCR4; green: Sox17; blue: DRAQ5
directed differentiation - StemMACS Trilineage Kit
In vitro directed differentiation
| Marker | Expressed |
| PDGFRB |
Yes |
Morphology
directed differentiation with StemMACS Trilineage assay: CD144 (enothelial cells) / CD140b = PDGFRB smooth muscle cells
directed differentiation with StemMACS Trilineage assay: CD144 (enothelial cells) / CD140b = PDGFRB smooth muscle cells (red); endothelial cells (CD144) green
Endothelial cells
In vitro directed differentiation
Morphology
directed differentiation with StemMACS Trilineage assay: CD144 (enothelial cells) / CD140b = PDGFRB smooth muscle cells
directed differentiation with StemMACS Trilineage assay: CD144 (enothelial cells) / CD140b = PDGFRB smooth muscle cells (red); endothelial cells (CD144) green
In vivo teratoma
In vitro directed differentiation
Morphology
K10 Ectoderm_ICC_Pax6 rot_Sox2 grün_ Draq5.tif
directed differentiation with StemMACS Trilineage assay: red = PAX6; green = SOX2; blue=DRAQ5
directed differentiation with StemMACS Trilineage assay: FC PAX6/SOX2
Microbiology / Virus Screening |
|
| HIV 1 | Negative |
| Hepatitis B | Negative |
| Hepatitis C | Negative |
| Mycoplasma | Negative |
Genotyping
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
|
Other Genotyping (Cell Line) |
|
Login to share your feedback, experiences or results with the research community.